<DOC>
	<DOCNO>NCT02430311</DOCNO>
	<brief_summary>This 2 part phase I , open label trial olaparib monotherapy olaparib combination paclitaxel patient solid tumour . Part A ass single multiple dose pharmacokinetics olaparib monotherapy multiple dose pharmacokinetics olaparib combination paclitaxel . Part B ass safety multiple dos olaparib Cohort 1 olaparib co-administered paclitaxel Cohort 2</brief_summary>
	<brief_title>The Pharmacokinetics Safety Olaparib Alone With Paclitaxel Chinese Patients With Advanced Solid Tumour .</brief_title>
	<detailed_description>Part A access pharmacokinetics olaparib : Cohort 1 investigate single multiple dose pharmacokinetics olaparib follow 300mg bd monotherapy dose ( ) ; Cohort 2 investigate single multiple dose pharmacokinetics olaparib follow 100mg bd monotherapy dose ( ) multiple dose pharmacokinetics presence co-administered paclitaxel ( 80mg/m2 weekly day 1 , 8 15 single 28-day cycle ) . In Part B : Safety profile olaparib 300mg bd monotherapy olaparib 100mg bd combination weekly paclitaxel also investigate Chinese patient .</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Olaparib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1 . Provision fully inform consent 2 . Patient age ≥ 18 year 3 . Histologically , appropriate , cytologically confirm malignant solid tumour refractory resistant standard therapy suitable effective standard therapy exist 4. life expectancy ≥ 12 week 5 . Patients Cohort 2 must eligible paclitaxel treatment 6 . Willing able comply protocol duration study include undergoing treatment schedule visit examination 7 . ECOG performance status ≤ 2 8 . Satisfactory organ bone marrow function measure within 28 day prior administration study treatment include Haemoglobin ≥ 10.0 g/dL blood transfusion 4 week prior first dose study drug . Absolute neutrophil count ≥ 1.5 × 109/L 9 . Evidence nonchildbearing status woman childbearing potential , postmenopausal status : negative urine serum pregnancy test within 28 day study treatment , confirm prior treatment Day 1 . 10 . Patients must stable concomitant medication regimen , define change medication dose within 2 week prior start olaparib dose , except bisphosphonates , denosumab corticosteroid , stable least 4 week prior start olaparib dosing . Exclusion criterion : 1 . Involvement plan and/or conduct study . 2 . Previous enrolment present study . 3 . Treatment investigational product last 14 day ( long period depend defined characteristic agent use ) . 4 . Any previous treatment Poly ( ADPribose ) polymerase ( PARP ) inhibitor , include olaparib . 5 . Patients malignancy within last 5 year , except adequately treat nonmelanoma skin cancer , curatively treated insitu cancer cervix , ductal carcinoma situ , Stage 1 , Grade 1 endometrial cancer , solid tumour include lymphoma ( without bone marrow involvement ) curatively treat evidence disease ≥5 year . 6 . Patients unable swallow orally administer medication patient gastrointestinal disorder likely interfere absorption study medication . These include patient gastric intestinal cancer patient prior surgical procedure full partial gastrectomy . 7 . Patients receive systemic chemotherapy , radiotherapy ( except palliative reason ) , within 4 week last dose prior study treatment . 8 . Concomitant use know potent CYP3A4 ( Cytochrome P450 3A4 ) inhibitor . 9 . Patients ongoing toxicity ( &gt; CTCAE ( Common Terminology Criteria Adverse Events ) grade 2 ) , exception alopecia , cause previous cancer therapy . 10 . Resting ECG QTc ( Heart Rate Corrected QT interval ) &gt; 470msec family history long QT syndrome . 11 . Patients interstitial pneumonia diffuse symptomatic fibrosis lung . 12 . Patients myelodysplastic syndrome/acute myeloid leukaemia . 13 . Patients symptomatic uncontrolled brain metastasis . 14 . Major surgery within 2 week start study treatment patient must recover effect major surgery . 15 . Patients consider poor medical risk due serious , uncontrolled medical disorder , nonmalignant systemic disease active , uncontrolled infection . 16 . Immunocompromised patient , e.g . patient know serologically positive human immunodeficiency virus ( HIV ) . 17 . Patients know active hepatic disease ( i.e . Hepatitis B C ) . 18 . Patients know hypersensitivity olaparib , paclitaxel excipients product . 19 . Breastfeeding woman . 20 . Clinical judgement investigator patient participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Chinese Patients</keyword>
</DOC>